4.4 Article

Interaction of small molecule inhibitors of HIV-1 entry with CCR5

Journal

VIROLOGY
Volume 349, Issue 1, Pages 41-54

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2006.01.018

Keywords

GPCR; CCR5; CCR5 inhibitors; HIV-1; TAK-779; AD101; SCH-C

Categories

Funding

  1. NIAID NIH HHS [R01 AI41420, R01 AI43847, T32 AI07621] Funding Source: Medline

Ask authors/readers for more resources

The CC-ebemokine receptor 5 (CCR5) is the major coreceptor for macrophage-tropic (R5) HIV-1 strains. Several small molecule inhibitors of CCR5 that block chemokine binding and HIV-1 entry are being evaluated as drug candidates. Here we define how CCR5 antagonists TAK-779, AD101 (SCH-350581) and SCH-C (SCH-351125), which inhibit HIV-1 entry, interact with CCR5. Using a mutagenesis approach in combination with a viral entry assay to provide a direct functional read out, we tested predictions based on a homology model of CCR5 and analyzed the functions of more than 30 amino acid residues. We find that a key set of aromatic and aliphatic residues serves as a hydrophobic core for the ligand binding pocket, while E283 is critical for high affinity interaction, most likely by acting as the counterion for a positively charged nitrogen atom common to all three inhibitors. These results provide a structural basis for understanding bow specific antagonists interact with CCR5, and may be useful for the rational design of new, improved CCR5 ligands. (c) 2006 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available